Included documentation may include: Mass Spectrometry Identity Verification Certificate of Analysis (COA) Research-Use-Only Documentation BlueNexLabs prioritizes consistency, transparency, and reproducibility across all peptide products supplied to Canadian researchers
Mr Mfazo Hove Featured in Newsweek: GLP-1 Medications and Vision Loss Posted Medically Reviewed by: Mr Mfazo Hove, Consultant Ophthalmic Surgeon Author: Chris Dunnington Published: July 16, 2026 Last Updated: July 16, 2026 Mr Mfazo Hove, Consultant Ophthalmic Surgeon and Medical Director of Blue Fin Vision, has been invited by Newsweek to comment on new international research linking GLP-1 medications to a rare optic nerve condition that can cause sudden vision loss
In November, it logged 108 crore in sales, becoming the highest-selling brand in the Indian Pharmaceutical Market, ahead of long-time leaders such as Augmentin, Glycomet GP and Pan
In OZEMPIC: Risks, Benefits, and Natural Alternatives to GLP-1 Weight-Loss Drugs, Dr